近日，由康方赛诺医药有限公司独立自主研发、全球首创的依沃西单抗注射液正式获批上市。依沃西单抗注射液联合化疗，有望为局部晚期或转移性非鳞状非小细胞肺癌患者提供一种全新高效的免疫治疗方案。
Our company currently operates a large-scale alpaca breeding base in the Donghu High-tech Zone of Wuhan. With a capacity for immunizing up to 100 adult animals annually, it is well-equipped to meet the demand for a substantial volume of antigen immunizations.
لم يتم إنشاء مقالات بعد
خدمة العملاء غير متاحة الآن عبر الموقع
Official support hours
الاثنين To الجمعة
From 9:00AM To 6:00PM